PMID- 21344354
OWN - NLM
STAT- MEDLINE
DCOM- 20110613
LR  - 20201216
IS  - 1098-8971 (Electronic)
IS  - 0272-8087 (Linking)
VI  - 31
IP  - 1
DP  - 2011 Feb
TI  - Revisiting the pathology of resected benign hepatocellular nodules using new 
      immunohistochemical markers.
PG  - 91-103
LID - 10.1055/s-0031-1272837 [doi]
AB  - In this review, the authors focus on the use of immunohistochemistry to 
      characterize the different types and subtypes of benign hepatocellular nodules. 
      They describe the classical and currently accepted features leading to the easy 
      and formal diagnosis of focal nodular hyperplasia (FNH) and hepatocellular 
      adenoma (HCA). In addition, they report some atypical features and difficulties 
      in the interpretation of section staining analyses, which represent important 
      parameters for pathologists. A significant contribution of molecular biology to 
      the characterization of FNH has been to reclassify some cases of FNH as 
      inflammatory HCA. Furthermore, the pattern of overexpression of glutamine 
      synthetase (GS), a target gene of beta-catenin has been successfully used to 
      identify FNH by immunohistochemistry. Molecular approaches have demonstrated that 
      HCA is a heterogeneous entity. Genotype classification of HCA has allowed the 
      identification of three subtypes: HNF1A-mutated HCA (H-HCA) in 35% of cases, 
      beta-catenin-mutated HCA (b-HCA) in 10%, and inflammatory HCA (IHCA) in 55%. 
      Following molecular data, the diagnosis of H-HCA relies on the lack of liver 
      fatty acid binding protein (LFABP) immunostaining. The diagnosis of b-HCA is 
      straightforward when GS is strongly and diffusely expressed by lesional 
      hepatocytes, and is accompanied by nuclear beta-catenin immunoreactivity. In IHCA, 
      serum amyloid protein and C- reactive protein are strongly and usually diffusely 
      expressed by tumoral hepatocytes with a sharp limit with the surrounding 
      nontumoral liver. IHCA can also be beta-catenin activated (10%). Due to the strong 
      association of b-HCA with hepatocellular carcinoma transformation, the 
      identification of this HCA subtype is extremely important.
CI  - (c) Thieme Medical Publishers.
FAU - Bioulac-Sage, Paulette
AU  - Bioulac-Sage P
AD  - Service d'Anatomie Pathologique, Hopital Pellegrin, CHU Bordeaux, Bordeaux Cedex 
      France. paulette.bioulac-sage@chu-bordeaux.fr
FAU - Cubel, Gaelle
AU  - Cubel G
FAU - Balabaud, Charles
AU  - Balabaud C
FAU - Zucman-Rossi, Jessica
AU  - Zucman-Rossi J
LA  - eng
PT  - Journal Article
DEP - 20110222
PL  - United States
TA  - Semin Liver Dis
JT  - Seminars in liver disease
JID - 8110297
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adenoma, Liver Cell/chemistry/*diagnosis/pathology/surgery
MH  - Adult
MH  - Biomarkers, Tumor/*analysis
MH  - Diagnosis, Differential
MH  - Female
MH  - Focal Nodular Hyperplasia/*diagnosis/metabolism/pathology/surgery
MH  - Humans
MH  - *Immunohistochemistry
MH  - Liver/*chemistry/pathology/surgery
MH  - Liver Neoplasms/chemistry/*diagnosis/pathology/surgery
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prognosis
EDAT- 2011/02/24 06:00
MHDA- 2011/06/15 06:00
CRDT- 2011/02/24 06:00
PHST- 2011/02/24 06:00 [entrez]
PHST- 2011/02/24 06:00 [pubmed]
PHST- 2011/06/15 06:00 [medline]
AID - 10.1055/s-0031-1272837 [doi]
PST - ppublish
SO  - Semin Liver Dis. 2011 Feb;31(1):91-103. doi: 10.1055/s-0031-1272837. Epub 2011 
      Feb 22.